Other small-molecule inhibitors targeting TGF-β signaling pathways, such as GFH018 and PF06952229, are under clinical evaluation for patients with lung cancer, breast cancer, and prostate cancer (Table 2). This evidence concerns the gene TGFB1 and breast carcinoma.